OncoMed Pharma (OMED) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
May 5, 2016 4:04 PM EDTOncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
Highlights AACR Presentations - Including Novel GITRL-Fc Candidate
Clinical Data on Vantictumab, Ipafricept, Demcizumab and Tarextumab Accepted for Presentation at ASCO
REDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED), a clinical-stage company developing novel anti-cancer stem cell (CSC) and immuno-oncology therapeutics, today reported first quarter financial results. The company also highlighted data presentations related to six oncology drug candidates, including robust... More
